Overview

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Status:
NOT_YET_RECRUITING

Trial end date:
2029-07-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.

Phase:

PHASE3

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

xanomeline